ZYLOXTB (02190) announces that the expected net profit attributable to shareholders of the company for the first half of the year will exceed 115 million yuan, an increase of approximately 66.9% compared to the same period last year.

ZYLOXTB (02190) announced that the group is expected to achieve revenues exceeding RMB 480 million in the first half of 2025, representing a year-on-year growth of approximately 31.1%. This significant increase is mainly driven by the sales of several key products including the Kirin Blood Flow Guiding Device, Neurovascular Guidewire, UltraFree Drug Eluting PTA Balloon Dilatation Catheter (UltraFree DCB), Octoplus Jugular Vein Filter, and Phoenix Peripheral Detachable Fiber Loop Embolization System. The net profit attributable to equity shareholders during the reporting period is expected to exceed RMB 115 million, representing a year-on-year growth of approximately 66.9%. This profit growth is mainly due to increased revenue generated from target sales work, improvement in product quality and operational efficiency leading to stable gross profit margin, and the implementation of efficient sales and marketing strategies.